Stockscreener 앱 받기
2.99
2.40%
0.07
시간 외 거래:
2.88
-0.11
-3.68%
전일 마감가:
$2.92
열려 있는:
$2.95
하루 거래량:
412.39K
Relative Volume:
0.44
시가총액:
$92.80M
수익:
$62.30M
순이익/손실:
$-53.83M
주가수익비율:
-11.17
EPS:
-0.2677
순현금흐름:
$-30.14M
1주 성능:
-5.38%
1개월 성능:
-15.77%
6개월 성능:
-20.27%
1년 성능:
+70.86%
1일 변동 폭
$2.885
$3.01
1주일 범위
$2.87
$3.18
52주 변동 폭
$1.325
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
명칭
Fortress Biotech Inc
전화
781-652-4500
주소
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
2.99 | 90.63M | 62.30M | -53.83M | -30.14M | -0.2677 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-15 | 재개 | ROTH MKM | Buy |
| 2022-08-04 | 개시 | Ladenburg Thalmann | Buy |
| 2020-10-02 | 개시 | The Benchmark Company | Buy |
| 2019-12-18 | 개시 | B. Riley FBR | Buy |
| 2018-02-28 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
| 2017-03-22 | 개시 | JMP Securities | Mkt Outperform |
| 2016-10-03 | 개시 | ROTH Capital | Buy |
모두보기
Fortress Biotech Inc 주식(FBIO)의 최신 뉴스
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire
Portfolio Shifts: Can Fortress Biotech Inc deliver alphaQuarterly Earnings Summary & Smart Money Movement Alerts - baoquankhu1.vn
Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Monday - MarketBeat
Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher - MSN
Buyback Watch: How liquid is Fortress Biotech Inc stock2026 Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Fortress Biotech (FBIO) CEO Lindsay Rosenwald reports 20.7% ownership in 13D/A - Stock Titan
Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares - Stock Titan
FORTRESS BIOTECH INC 9.375% Cumulative Redeemable Preferred Stock Series A USD25.00 (FBIOP.US) will release its earnings report after the market closes on March 25. - 富途牛牛
Mustang Bio, Inc. 2025 Annual Report: Clinical-Stage Biopharmaceutical Pipeline, Risks, and Regulatory Overview - Minichart
Mustang Bio (NASDAQ: MBIO) details GBM pipeline, Orphan status and cash - Stock Titan
Fortress Biotech (NASDAQ:FBIO) Cut to "Hold" at Zacks Research - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Macro Review: How do insiders feel about Fortress Biotech IncMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Understanding Momentum Shifts in (FBIOP) - Stock Traders Daily
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - The Globe and Mail
Quarterly Earnings: Should value investors consider Fortress Biotech Inc2026 Growth vs Value & Consistent Profit Trade Alerts - baoquankhu1.vn
Fortress Biotech Inc Stock (ISIN: US32015L1035) Faces Short Interest Pressure Amid Biotech Sector Vo - AD HOC NEWS
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Swing Trade: How do insiders feel about Fortress Biotech IncCEO Change & Daily Technical Forecast Reports - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (FBIOP) Movement - Stock Traders Daily
Aug Sectors: How do insiders feel about Fortress Biotech IncMarket Performance Recap & Technical Entry and Exit Tips - baoquankhu1.vn
Aug Opening: What are the risks of holding Fortress Biotech IncJuly 2025 PreEarnings & Risk Controlled Swing Alerts - baoquankhu1.vn
Why Is Fortress Biotech Stock Falling Today? - Stocktwits
FBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Weekly Trades: Will Fortress Biotech Inc outperform during market ralliesTreasury Yields & Technical Pattern Recognition Alerts - baoquankhu1.vn
Gap Down: Will Fortress Biotech Inc outperform during market ralliesNew Guidance & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Discipline and Rules-Based Execution in FBIOP Response - Stock Traders Daily
Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M - Yahoo Finance
Fortress Biotech’s (FBIO) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
FBIO: HC Wainwright & Co. Reiterates Buy Rating on Fortress Biot - GuruFocus
FBIO Eyes Future Growth Amid Financial Optimism - StocksToTrade
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy - Stocktwits
FBIO: HC Wainwright & Co. Reiterates Buy Rating on Fortress Biotech | FBIO Stock News - GuruFocus
Fortress Biotech Inc. Shares Soar After Promising New Developments - timothysykes.com
Fortress Biotech's (FBIO) Buy Rating Reiterated at HC Wainwright - MarketBeat
Fortress Biotech: PRV Windfall and De-Risked Zycubo Economics Support Buy Rating and $17 Target - TipRanks
Fortress Biotech (FBIO) Sells Priority Review Voucher for $205 M - GuruFocus
Fortress Biotech Inc. Faces Stock Volatility Amid Strategic Adjustments - StocksToTrade
Fortress Biotech, Inc. and Cyprium Therapeutics Enter Asset Purchase Agreement for $205 Million Rare Pediatric Disease Priority Review Voucher - Quiver Quantitative
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics - GlobeNewswire
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - Yahoo Finance
Strategic Acquisition Sends Fortress Biotech Stocks Soaring - timothysykes.com
Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - marketscreener.com
Cyprium Voucher Sale Bolsters Fortress Biotech Liquidity - TipRanks
Fortress Biotech Monetizes PRV for $205 Million; Amends Oaktree Credit Facility - TradingView
After Menkes drug approval, Fortress moves to cash in $205M voucher - Stock Titan
Avenue Therapeutics Enters into Exclusive Worldwide License - GlobeNewswire
Gains Recap: What is Fortress Biotech Incs revenue forecastEarnings Performance Report & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Insider Trends: Can SVIIU navigate macro headwindsJuly 2025 Selloffs & Weekly Market Pulse Updates - baoquankhu1.vn
Fortress Biotech Inc (FBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):